In vivo studies using ovarian carcinoma xenografts in immunodeficient mice demonstrated that ‘NK-centric’ CAR transduced NK cells displayed superior anti-tumor activity, reduced tumor burden, and improved mouse survival when compared to NK cells transduced with traditional CARs containing the T cell signaling domain, CD28. Here, CD28 is linked to neoplasm.